Given the tolerability of this combination in vivo, our results suggest that brimarafenib and mirdametinib represent a promising therapeutic strategy for patients with NRAS‐mutated melanomas and potentially other RAS‐mutated solid tumors. Here, NRAS is linked to melanoma.